Evidence map›Paper›PMID 41822553›Full record

ArticleJournal of clinical and translational science2026

Using a participation monitoring database to enhance recruitment in a rare cancer population.

Michael A O'Rorke, Brian M Gryzlak, Tao Xu, Bradley D McDowell, Rhonda R DeCook, Nicholas J Rudzianski, Kimberly C Serrano, Abigayle M Wehrheim, Udhayvir S Grewal, Chandrikha Chandrasekharan and 22 more

Abstract read
In one paragraph

Article in Journal of clinical and translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Michael A O'RorkeEpidemiology, The University of Iowa, USA.ORCID https://orcid.org/0000-0002-2425-3323
Brian M GryzlakEpidemiology, The University of Iowa, USA.
Tao XuEpidemiology, The University of Iowa, USA.
Bradley D McDowellThe University of Iowa Holden Comprehensive Cancer Center, USA.
Rhonda R DeCookEpidemiology, The University of Iowa, USA.
Nicholas J RudzianskiEpidemiology, The University of Iowa, USA.
Kimberly C SerranoEpidemiology, The University of Iowa, USA.
Abigayle M WehrheimEpidemiology, The University of Iowa, USA.
Udhayvir S GrewalInternal Medicine, The University of Iowa Roy J and Lucille A Carver College of Medicine, USA.
Chandrikha ChandrasekharanGastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, USA.
Joseph S DillonInternal Medicine, The University of Iowa Roy J and Lucille A Carver College of Medicine, USA.
Thorvardur R HalfdanarsonMedical Oncology, Mayo Clinic Minnesota, USA.
Michael J SchnellMayo Clinic Minnesota, USA.
Carrie L WitterMayo Clinic Minnesota, USA.
T Clark GamblinMedical College of Wisconsin, USA.
Syed KazmiInternal Medicine, UT Southwestern Medical Center, USA.
Lindsay G CowellO'Donnell School of Public Health, UT Southwestern Medical Center, USA.
Tobias ElseInternal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan, USA.
Heloisa P SoaresUniversity of Utah Health Huntsman Cancer Institute, USA.
Vineeth SukrithanDivision of Medical Oncology, Department of Medicine, The Ohio State University, USA.
Sravani ChandakaThe University of Kansas Medical Center, USA.
Hanna K SanoffDivision of Oncology, The University of North Carolina at Chapel Hill School of Medicine, USA.
Fiona C HeAllina Health Cancer Institute, USA.
David A GellerUniversity of Pittsburgh, USA.
Robert A RamirezDepartment of Internal Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, USA.
Mei LiuHealth Outcomes and Biomedical Informatics, University of Florida, USA.ORCID https://orcid.org/0000-0002-8036-2110
William LancasterSurgery, Medical University of South Carolina, USA.
Josh A MailmanNorCal CarciNET Community, USA.
Heather MoranThe Healing NET Foundation, USA.
Maryann WahmannNeuroendocrine Cancer Awareness Network, USA.
Elyse GellermanNeuroendocrine Tumor Research Foundation, USA.
Elizabeth A ChrischillesEpidemiology, The University of Iowa, USA.

Funding

University of Iowa Institute for Clinical and Translational ScienceUM1TR004403 · NCATS · UNIVERSITY OF IOWA · PI Marlan R Hansen, Patricia Winokur · 2023 to 2026
$16.1M
Project 3: GLP1R and GIPR Agonists in GEP NETs ProjectP50CA302572 · NCI · UNIVERSITY OF IOWA · PI JAMES R HOWE, Yusuf Menda · 2025 to 2026
$6.5M
NCATS NIH HHS UM1 TR004403NCI NIH HHS P50 CA302572
6 · The paper itself

Abstract

Introduction: Recruitment for rare disease studies is challenging due to small eligible populations. Traditional clinical research management systems often lack tools to track recruitment contacts prior to enrollment. The NET-PRO study, focused on neuroendocrine tumors (NETs), implemented a participation monitoring system to enhance recruitment efficiency and representativeness. Methods: NET-PRO is a multicenter cohort study of 2538 adults diagnosed with gastroenteropancreatic (GEP) or lung NETs between January 2018 and September 2024. Recruitment occurred from January 2022 to February 2025 across 14 U.S. medical centers. Sites used flexible recruitment methods (email, mail, phone, in-clinic) and tracked contacts using REDCap-based tools. Participant characteristics were analyzed by enrollment mode (online or mail) and recruitment difficulty (number of contacts required prior to enrollment) using standardized mean differences, chi-square tests, and ANOVA. Results: Of 9279 contacted patients, 2675 consented (28.8%) and 2538 enrolled (27.4%). Most enrolled online (83.2%), while 16.8% enrolled by mail. Mail respondents were older, had lower education and income, and more comorbidities. Among those enrolled, recruitment difficulty was associated with older age, lower education and income, but not comorbidity. Over half of the most difficult-to-recruit participants enrolled online. Contact methods varied by attempt, with email dominating early contacts and phone/mail used more in later attempts. Conclusions: A participation monitoring tool supported flexible, multimodal recruitment and improved sample representativeness in a rare cancer study. Tracking recruitment contacts enabled adaptive strategies and may reduce bias in observational research by enabling better outreach to harder-to-reach populations.

Indexed as

data collectionneuroendocrinerare diseasesRecruitmentrepresentativeness

Identifiers

PMID41822553
PMCPMC12975625

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.